{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:06:50Z","timestamp":1792739210946,"version":"4.5.0"},"reference-count":93,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their potential, these therapies have had limited success in late-phase trials for advanced cancer resulting in few formal approvals. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to determine how to design clinical trials with the greatest chance of demonstrating the benefits of intratumoral immunotherapy for patients with cancers across all stages of pathogenesis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An Intratumoral Immunotherapy Clinical Trials Expert Panel composed of international key stakeholders from academia and industry was assembled. A multiple choice\/free response survey was distributed to the panel, and the results of this survey were discussed during a half-day consensus meeting. Key discussion points are summarized in the following manuscript.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The panel determined unique clinical trial designs tailored to different stages of cancer development\u2014from premalignant to unresectable\/metastatic\u2014that can maximize the chance of capturing the effect of intratumoral immunotherapies. Design elements discussed included study type, patient stratification and exclusion criteria, indications of randomization, study arm determination, endpoints, biological sample collection, and response assessment with biomarkers and imaging. Populations to prioritize for the study of intratumoral immunotherapy, including stage, type of cancer and line of treatment, were also discussed along with common barriers to the development of these local treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The SITC Intratumoral Immunotherapy Clinical Trials Expert Panel has identified key considerations for the design and implementation of studies that have the greatest potential to capture the effect of intratumorally delivered immunotherapies. With more effective and standardized trial designs, the potential of intratumoral immunotherapy can be realized and lead to regulatory approvals that will extend the benefit of these local treatments to the patients who need them the most.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-008378","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T04:20:13Z","timestamp":1713500413000},"page":"e008378","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J","family":"Luke","sequence":"first","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-8055","authenticated-orcid":false,"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H","family":"Andtbacka","sequence":"additional","affiliation":[{"name":"HiFiBiO Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Brody","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-8278","authenticated-orcid":false,"given":"Jason","family":"Chesney","sequence":"additional","affiliation":[{"name":"James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coffin","sequence":"additional","affiliation":[{"name":"Replimune Inc, Woburn, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"de Baere","sequence":"additional","affiliation":[{"name":"Center for Biotherapies In Situ (BIOTHERIS), INSERM CIC1428, Interventional Radiology Unit, Department of Medical Imaging, Gustave Roussy Cancer Center, University of Paris Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D","family":"de Gruijl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands"},{"name":"Cancer Immunology, Amsterdam Institute for Infection and Immunology, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Fury","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-6146","authenticated-orcid":false,"given":"Gregory","family":"Goldmacher","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J","family":"Harrington","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, The Royal Marsden National Institute for Health and Care Research Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Ankyra Therapeutics, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara M","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha D","family":"Khilnani","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[{"name":"Marengo Therapeutics, Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[{"name":"Division of Cancer Research, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia"},{"name":"The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, North Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"CIMA, Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-1685","authenticated-orcid":false,"given":"Mark","family":"Middleton","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-5903","authenticated-orcid":false,"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Jette, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK"},{"name":"Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-8985","authenticated-orcid":false,"given":"Rahul A","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Solomon","sequence":"additional","affiliation":[{"name":"Chief of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Professor of Radiology, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Szapary","sequence":"additional","affiliation":[{"name":"Interventional Oncology, Johnson & Johnson, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aurelien","family":"Marabelle","sequence":"additional","affiliation":[{"name":"Center for Biotherapies In Situ (BIOTHERIS), INSERM CIC1428, Department for Therapeutic Innovation and Early Phase Trials (DITEP), Gustave Roussy Cancer Center, University of Paris Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2025100301322626000_12.4.e008378.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100301322626000_12.4.e008378.2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100301322626000_12.4.e008378.3","unstructured":"Idera Pharmaceuticals, Inc . Idera pharmaceuticals announces results from illuminate-301 trial of Tilsotolimod + Ipilimumab in anti-PD-1 refractory advanced Melanoma. news release; 2021."},{"key":"2025100301322626000_12.4.e008378.4","unstructured":"Oncosec Immunotherapies . Oncosec announces clinical data of the KEYNOTE-695 trial assessing TAVO-EP in combination with KEYTRUDA (Pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. press release; 2023."},{"key":"2025100301322626000_12.4.e008378.5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4103\/JCAS.JCAS_109_20","article-title":"Intralesional agents in dermatology: pros and cons","volume":"14","author":"Sakhiya","year":"2021","journal-title":"J Cutan Aesthet Surg"},{"key":"2025100301322626000_12.4.e008378.6","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-12-0275"},{"key":"2025100301322626000_12.4.e008378.7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1A melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"key":"2025100301322626000_12.4.e008378.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.11.066"},{"key":"2025100301322626000_12.4.e008378.9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100301322626000_12.4.e008378.10","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(91)80166-5"},{"key":"2025100301322626000_12.4.e008378.11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1992.01680210064008"},{"key":"2025100301322626000_12.4.e008378.12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000246688","article-title":"Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma","volume":"190","author":"Chimenti","year":"1995","journal-title":"Dermatology"},{"key":"2025100301322626000_12.4.e008378.13","unstructured":"de Gruijl T , ed. Functional assessment of immune responses and identification of new antigens. European Society of Medical Oncology Preceptorship Programme: Immuno-Oncology from the Essentials of Tumour Immunology to linical application; Amsterdam, Netherlands.2017"},{"key":"2025100301322626000_12.4.e008378.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y"},{"key":"2025100301322626000_12.4.e008378.15","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0811-x","article-title":"TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma","volume":"7","author":"Reilley","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100301322626000_12.4.e008378.16","first-page":"A623-A","article-title":"595 Flt3L-primed in situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER\/PR+ breast cancer","volume":"10","author":"Marron","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100301322626000_12.4.e008378.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153902","article-title":"Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (PANFIRE-III). A phase-I study protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100301322626000_12.4.e008378.18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5286-0"},{"key":"2025100301322626000_12.4.e008378.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.017"},{"key":"2025100301322626000_12.4.e008378.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4459"},{"key":"2025100301322626000_12.4.e008378.21","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12093"},{"key":"2025100301322626000_12.4.e008378.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05838-7"},{"key":"2025100301322626000_12.4.e008378.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature25432"},{"key":"2025100301322626000_12.4.e008378.24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-020-2698-6","article-title":"Pervasive chromosomal instability and karyotype order in tumour evolution","volume":"587","author":"Watkins","year":"2020","journal-title":"Nature"},{"key":"2025100301322626000_12.4.e008378.25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2614","article-title":"Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy","volume":"11","author":"Momin","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100301322626000_12.4.e008378.26","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn5859","article-title":"Intratumoral immunotherapy relies on B and T cell collaboration","volume":"7","author":"Sagiv-Barfi","year":"2022","journal-title":"Sci Immunol"},{"key":"2025100301322626000_12.4.e008378.27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64859"},{"key":"2025100301322626000_12.4.e008378.28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"Cd40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"2025100301322626000_12.4.e008378.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"2025100301322626000_12.4.e008378.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1866"},{"key":"2025100301322626000_12.4.e008378.31","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0605-1","article-title":"Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node","volume":"7","author":"van Pul","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100301322626000_12.4.e008378.32","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ccell.2022.06.009","article-title":"Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma","volume":"40","author":"van Krimpen","year":"2022","journal-title":"Cancer Cell"},{"key":"2025100301322626000_12.4.e008378.33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"2025100301322626000_12.4.e008378.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"2025100301322626000_12.4.e008378.35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay3575","article-title":"Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy","volume":"12","author":"Francis","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100301322626000_12.4.e008378.36","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8097","article-title":"Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T(Reg) reduction and effector T cell activation","volume":"7","author":"van Pul","year":"2022","journal-title":"Sci Immunol"},{"key":"2025100301322626000_12.4.e008378.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0944"},{"key":"2025100301322626000_12.4.e008378.38","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100301322626000_12.4.e008378.39","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","article-title":"1037O MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1C melanoma (MEL)","volume":"32","author":"Ribas","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100301322626000_12.4.e008378.40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.08.034","article-title":"High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy","volume":"177","author":"Dercle","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025100301322626000_12.4.e008378.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29286-5","article-title":"The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity","volume":"13","author":"Maurer","year":"2022","journal-title":"Nat Commun"},{"key":"2025100301322626000_12.4.e008378.42","unstructured":"FDA . Project optimus: reforming the dose optimization and dose selection paradigm in oncology. 2023. Available: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus"},{"key":"2025100301322626000_12.4.e008378.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01127.x"},{"key":"2025100301322626000_12.4.e008378.44","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaoncol.2023.2789","article-title":"Final 5-year follow-up results evaluating neoadjuvant talimogene laherparepvec plus surgery in advanced melanoma","volume":"9","author":"Dummer","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025100301322626000_12.4.e008378.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"2025100301322626000_12.4.e008378.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100301322626000_12.4.e008378.47","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2025100301322626000_12.4.e008378.48","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.19.02985","article-title":"Response criteria for intratumoral immunotherapy in solid tumors: itRECIST","volume":"38","author":"Goldmacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100301322626000_12.4.e008378.49","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu342.23","article-title":"Adaptation of the immune related response criteria: irrecist","volume":"25","author":"Bohnsack","year":"2014","journal-title":"Ann Oncol"},{"key":"2025100301322626000_12.4.e008378.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025100301322626000_12.4.e008378.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100301322626000_12.4.e008378.52","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1476-5381.2010.01160.x","article-title":"Development of radiotracers for oncology--the interface with pharmacology","volume":"163","author":"Sharma","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2025100301322626000_12.4.e008378.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09834-2","article-title":"Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions","volume":"10","author":"Beane","year":"2019","journal-title":"Nat Commun"},{"key":"2025100301322626000_12.4.e008378.54","doi-asserted-by":"crossref","unstructured":"Karunamurthy A , Chauvin J-M , Morrison R , et al . 605 Neoadjuvant vidutolimod (Vidu) and nivolumab (Nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results. J Immunother Cancer 2022:A634\u20135. doi:10.1136\/jitc-2022-SITC2022.0605","DOI":"10.1136\/jitc-2022-SITC2022.0605"},{"key":"2025100301322626000_12.4.e008378.55","doi-asserted-by":"crossref","unstructured":"Tarhini A , Eroglu Z , Sarnaik A , et al . 617 Neoadjuvant intratumoral TAVO-EP (Plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma. J ImmunoTher Cancer 2022. doi:10.1136\/jitc-2022-SITC2022.0617","DOI":"10.1136\/jitc-2022-SITC2022.0617"},{"key":"2025100301322626000_12.4.e008378.56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy218"},{"key":"2025100301322626000_12.4.e008378.57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2379"},{"key":"2025100301322626000_12.4.e008378.58","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.annonc.2020.07.016","article-title":"Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma","volume":"31","author":"Tetzlaff","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100301322626000_12.4.e008378.59","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","article-title":"Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant Immunotherapy in stage III melanoma","volume":"32","author":"Rawson","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100301322626000_12.4.e008378.60","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1203475420988862","article-title":"Durability of complete response to intralesional interleukin-2 for in-transit melanoma","volume":"25","author":"Khoury","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"2025100301322626000_12.4.e008378.61","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ijc.32172","article-title":"High response rates for T-VEC in early metastatic melanoma (stage IIIB\/C-IVM1A)","volume":"145","author":"Franke","year":"2019","journal-title":"Int J Cancer"},{"key":"2025100301322626000_12.4.e008378.62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100301322626000_12.4.e008378.63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3065"},{"key":"2025100301322626000_12.4.e008378.64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x"},{"key":"2025100301322626000_12.4.e008378.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2025100301322626000_12.4.e008378.66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0672"},{"key":"2025100301322626000_12.4.e008378.67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3365"},{"key":"2025100301322626000_12.4.e008378.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04847-2"},{"key":"2025100301322626000_12.4.e008378.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.09.065"},{"key":"2025100301322626000_12.4.e008378.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.128"},{"key":"2025100301322626000_12.4.e008378.71","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on- and off-ramps of oncology accelerated approval","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100301322626000_12.4.e008378.72","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0075"},{"key":"2025100301322626000_12.4.e008378.73","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100301322626000_12.4.e008378.74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Mu\u00f1oz","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100301322626000_12.4.e008378.75","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1042\/EBC20220248","article-title":"Immunologically relevant effects of radiation therapy on the tumor microenvironment","volume":"67","author":"Galassi","year":"2023","journal-title":"Essays Biochem"},{"key":"2025100301322626000_12.4.e008378.76","unstructured":"FDA . Drugs@FDA: FDA-approved drugs. 2023. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"2025100301322626000_12.4.e008378.77","doi-asserted-by":"crossref","unstructured":"Ghiringhelli F , Bruchard M , Apetoh L . Immune effects of 5-fluorouracil: ambivalence matters. Oncoimmunology March 2013. doi:10.4161\/onci.23139","DOI":"10.4161\/onci.23139"},{"key":"2025100301322626000_12.4.e008378.78","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol"},{"key":"2025100301322626000_12.4.e008378.79","first-page":"18","article-title":"Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule","volume":"74","author":"Jorizzo","year":"2004","journal-title":"Cutis"},{"key":"2025100301322626000_12.4.e008378.80","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.562"},{"key":"2025100301322626000_12.4.e008378.81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","article-title":"Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"128","author":"Brosman","year":"1982","journal-title":"J Urol"},{"key":"2025100301322626000_12.4.e008378.82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110243251703"},{"key":"2025100301322626000_12.4.e008378.83","unstructured":"FDA . FDA approves first adenoviral vector-based gene therapy for high-risk bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer. Press release; 2022."},{"key":"2025100301322626000_12.4.e008378.84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0657"},{"key":"2025100301322626000_12.4.e008378.85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3690"},{"key":"2025100301322626000_12.4.e008378.86","doi-asserted-by":"publisher","DOI":"10.1126\/science.1208347"},{"key":"2025100301322626000_12.4.e008378.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024"},{"key":"2025100301322626000_12.4.e008378.88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915"},{"key":"2025100301322626000_12.4.e008378.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.201606.049"},{"key":"2025100301322626000_12.4.e008378.90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002552","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer","volume":"9","author":"Galsky","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100301322626000_12.4.e008378.91","unstructured":"FDA . Highlights of prescribing information: Aldara\u00ae (Imiquimod) cream, 5% 2010; 2010."},{"key":"2025100301322626000_12.4.e008378.92","unstructured":"Network NCC . NCCN guidelines version 2.2019: penile cancer; 2019."},{"key":"2025100301322626000_12.4.e008378.93","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:32:38Z","timestamp":1759480358000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,18]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/jitc-2023-008378"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008378","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}